ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 431,04
-0,79%
Dow Jones
41 938,45
-1,63%
DAX
20 214,79
-0,51%
Brent Oil
79,285
0,00%
Bitcoin
93 949,08
-0,66%
Registration Strip Icon for charts Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Y mAbs Therapeutics Inc (YMAB)

  7. Y mAbs Therapeutics Inc (YMAB) Actualités

YMAB

Y mAbs Therapeutics (YMAB)

Y mAbs Therapeutics Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:YMAB
DateHeureSourceTitreSymboleSociété
10/01/202515h27Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:YMABY mAbs Therapeutics Inc
10/01/202515h26GlobeNewswire Inc.Correcting & Replacing – Y-mAbs Provides Strategic Business Update and 2025 PrioritiesNASDAQ:YMABY mAbs Therapeutics Inc
10/01/202513h35GlobeNewswire Inc.Y-mAbs Appoints Experienced Commercial Leader as Head of DANYELZA Business UnitNASDAQ:YMABY mAbs Therapeutics Inc
10/01/202513h05GlobeNewswire Inc.Y-mAbs Provides Strategic Business Update and 2025 PrioritiesNASDAQ:YMABY mAbs Therapeutics Inc
23/12/202413h30GlobeNewswire Inc.Y-mAbs to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceNASDAQ:YMABY mAbs Therapeutics Inc
07/12/202418h00GlobeNewswire Inc.Y-mAbs Presents SADA Platform Preclinical Data and Trial in Progress Posters at the 2024 American Society Hematology (ASH) Annual MeetingNASDAQ:YMABY mAbs Therapeutics Inc
27/11/202413h35GlobeNewswire Inc.Y-mAbs to Participate at Citi’s 2024 Global Healthcare ConferenceNASDAQ:YMABY mAbs Therapeutics Inc
14/11/202422h32Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:YMABY mAbs Therapeutics Inc
08/11/202413h18Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:YMABY mAbs Therapeutics Inc
08/11/202412h35GlobeNewswire Inc.Y-mAbs Reports Third Quarter 2024 Financial Results and Recent Corporate DevelopmentsNASDAQ:YMABY mAbs Therapeutics Inc
04/11/202413h35GlobeNewswire Inc.Y-mAbs and Nobelpharma Announce Exclusive License and Distribution Agreement for DANYELZA® (naxitamab-gqgk) in JapanNASDAQ:YMABY mAbs Therapeutics Inc
25/10/202413h05GlobeNewswire Inc.Y-mAbs Announces Third Quarter 2024 Conference Call and WebcastNASDAQ:YMABY mAbs Therapeutics Inc
01/10/202413h05GlobeNewswire Inc.Y-mAbs to Participate in Upcoming Investor Conferences in OctoberNASDAQ:YMABY mAbs Therapeutics Inc
20/09/202422h15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:YMABY mAbs Therapeutics Inc
13/09/202422h19Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:YMABY mAbs Therapeutics Inc
06/09/202413h30GlobeNewswire Inc.Y-mAbs Presents Neuroblastoma Research on Naxitamab and SADA PRIT Technology Platform at AACR Special Conference on Advances in Pediatric Cancer ResearchNASDAQ:YMABY mAbs Therapeutics Inc
03/09/202414h32GlobeNewswire Inc.Y-mAbs to Participate in Upcoming Investor Conferences in SeptemberNASDAQ:YMABY mAbs Therapeutics Inc
12/08/202412h30GlobeNewswire Inc.Y-mAbs Reports Second Quarter 2024 Financial Results and Recent Corporate DevelopmentsNASDAQ:YMABY mAbs Therapeutics Inc
07/08/202413h05GlobeNewswire Inc.Y-mAbs to Participate in Upcoming Investor Conferences in AugustNASDAQ:YMABY mAbs Therapeutics Inc
05/08/202422h05GlobeNewswire Inc.Y-mAbs Announces Second Quarter 2024 Conference Call and WebcastNASDAQ:YMABY mAbs Therapeutics Inc
01/07/202422h05GlobeNewswire Inc.Y-mAbs Appoints Seasoned Biopharma Executive Peter Pfreundschuh as Chief Financial OfficerNASDAQ:YMABY mAbs Therapeutics Inc
07/06/202413h05GlobeNewswire Inc.Y-mAbs Announces Preclinical GD2-SADA Data to be Presented at 2024 SNMMI Annual MeetingNASDAQ:YMABY mAbs Therapeutics Inc
05/06/202413h05GlobeNewswire Inc.Y-mAbs Deepens Radiopharmaceutical Leadership with Appointment of Norman LaFrance, M.D. as Chief Development OfficerNASDAQ:YMABY mAbs Therapeutics Inc
01/06/202414h15GlobeNewswire Inc.Y-mAbs Announces Publication of Preclinical GD2-SADA Data at 2024 ASCO Annual MeetingNASDAQ:YMABY mAbs Therapeutics Inc
01/06/202414h05GlobeNewswire Inc.Y-mAbs Announces New Interim Analysis of Phase 2 Data for Naxitamab at 2024 ASCO Annual MeetingNASDAQ:YMABY mAbs Therapeutics Inc
07/05/202422h05GlobeNewswire Inc.Y-mAbs Reports First Quarter 2024 Financial Results and Recent Corporate DevelopmentsNASDAQ:YMABY mAbs Therapeutics Inc
26/04/202413h05GlobeNewswire Inc.Y-mAbs to Announce First Quarter 2024 Financial and Operating Results on May 7, 2024NASDAQ:YMABY mAbs Therapeutics Inc
25/04/202422h05GlobeNewswire Inc.Y-mAbs to Present at 2024 ASCO Annual MeetingNASDAQ:YMABY mAbs Therapeutics Inc
14/03/202414h05GlobeNewswire Inc.Y-mAbs Therapeutics Announces Resignation of Chief Financial OfficerNASDAQ:YMABY mAbs Therapeutics Inc
04/03/202413h30GlobeNewswire Inc.Y-mAbs Appoints Oncology Executive Mary Tagliaferri, M.D. to its Board of DirectorsNASDAQ:YMABY mAbs Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:YMAB

Dernières Valeurs Consultées

BOV
CEDO3R
CEDRO ON
BOV
AZZA3
AZZAS 2154 ON
BIT
UB7X7A
Unicredit Bank
BIT
1ORCL
Oracle
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2025 ADVFN PLC - Tous droits réservés